Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Abiomed Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abiomed Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
The financial data reveals several notable trends in profitability and return metrics over the six-year period.
- Gross Profit Margin
- The gross profit margin displayed a gradual decline from 84.14% in 2017 to 81.76% in 2022. Despite this downward trend, the margin remained relatively high and stable, indicating sustained efficiency in production or service delivery costs relative to revenue.
- Operating Profit Margin
- The operating profit margin saw an initial upward trend, increasing from 20.24% in 2017 to a peak of 29.64% in 2020. Afterward, a noticeable decline occurred, dropping sharply to 13.64% by 2022. This fluctuation suggests that operating efficiency improved steadily until 2020 but then deteriorated significantly, possibly due to increased operating expenses or other challenges affecting core business operations.
- Net Profit Margin
- Net profit margin exhibited substantial variation, rising from 11.7% in 2017 to a peak of 33.66% in 2019, which indicates possibly favorable non-operating income or tax benefits during that year. Although it declined thereafter, it remained above the initial level until 2021 before dropping to 13.23% in 2022. The decline toward the end of the period suggests increased costs or reduced profitability impacting overall earnings.
- Return on Equity (ROE)
- ROE followed a similar pattern to net profit margin, improving from 11.53% in 2017 to 27.65% in 2019, indicating enhanced shareholder value creation during that timeframe. However, subsequent years showed a decline to 9.08% in 2022, implying reduced efficiency in generating profit from shareholder investments.
- Return on Assets (ROA)
- ROA trends closely mirror those of ROE, with growth from 9.47% in 2017 to 24.57% in 2019, followed by a decrease to 8.16% in 2022. This pattern reflects a decline in asset utilization efficiency and profitability in later years.
Overall, the data indicates that while core profitability and returns improved substantially until around 2019-2020, the subsequent period experienced notable declines across all key profitability and return metrics. This suggests the company faced operational and financial challenges in the latter years that impacted its efficiency and profitability.
Return on Sales
Return on Investment
Gross Profit Margin
Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||
Gross profit | |||||||
Revenue | |||||||
Profitability Ratio | |||||||
Gross profit margin1 | |||||||
Benchmarks | |||||||
Gross Profit Margin, Competitors2 | |||||||
Abbott Laboratories | |||||||
Elevance Health Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
1 2022 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenue
= 100 × ÷ =
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue exhibited consistent growth from 2017 through 2022, increasing from approximately $445 million to over $1 billion. The growth accelerated notably in the later years, particularly between 2021 and 2022, indicating expanding sales or service activity in the business.
- Gross Profit Trends
- Gross profit followed a similar upward trajectory, rising steadily from $375 million in 2017 to $844 million in 2022. This growth mirrors the revenue trend and suggests effective management of cost of goods sold or improved operational efficiency contributing to enhanced profitability.
- Gross Profit Margin Analysis
- The gross profit margin showed a declining trend from 84.14% in 2017 to 80.9% in 2021, with a slight recovery to 81.76% in 2022. Despite the decrease in margin percentage, the absolute gain in gross profit indicates that volume growth outweighed margin compression. The initial decline in margin could be reflective of increased cost pressures or changes in sales mix.
- Overall Financial Performance Insights
- The data reveals robust revenue and gross profit growth over the six-year period, though accompanied by a slight erosion of gross margin percentage. The company appears to be scaling its operations effectively; however, the downward margin trend may warrant attention to cost control or pricing strategies to sustain profitability levels going forward.
Operating Profit Margin
Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||
Income from operations | |||||||
Revenue | |||||||
Profitability Ratio | |||||||
Operating profit margin1 | |||||||
Benchmarks | |||||||
Operating Profit Margin, Competitors2 | |||||||
Abbott Laboratories | |||||||
Elevance Health Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
Operating Profit Margin, Sector | |||||||
Health Care Equipment & Services | |||||||
Operating Profit Margin, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
1 2022 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenue
= 100 × ÷ =
2 Click competitor name to see calculations.
The financial data reveals distinct trends over the six-year period ending March 31, 2022.
- Income from Operations
- There is a general upward trend from 2017 through 2020, with income increasing from 90,138 thousand US dollars in 2017 to a peak of 249,219 thousand US dollars in 2020. However, the subsequent two years show a decline in income from operations, falling to 229,557 thousand in 2021 and then significantly dropping to 140,720 thousand in 2022.
- Revenue
- Revenue demonstrates consistent growth throughout the entire period. Starting at 445,304 thousand US dollars in 2017, revenue increased every year, ending at 1,031,753 thousand US dollars in 2022, which represents more than a twofold increase from the initial year.
- Operating Profit Margin
- The operating profit margin improved steadily from 20.24% in 2017 to a high of 29.64% in 2020, indicating increasing operational efficiency or profitability relative to revenue. This margin then declined to 27.09% in 2021, followed by a sharp decrease to 13.64% in 2022, suggesting rising costs or other factors adversely impacting profitability despite growing revenue.
In summary, while revenue consistently expanded over the analyzed years, income from operations peaked in 2020 and then experienced a notable decrease, mirroring the pattern seen in the operating profit margin. The sharp decline in profitability in 2022 despite increasing revenue suggests potential challenges in cost management or other operational issues that warrant further investigation.
Net Profit Margin
Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||
Net income | |||||||
Revenue | |||||||
Profitability Ratio | |||||||
Net profit margin1 | |||||||
Benchmarks | |||||||
Net Profit Margin, Competitors2 | |||||||
Abbott Laboratories | |||||||
Elevance Health Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
Net Profit Margin, Sector | |||||||
Health Care Equipment & Services | |||||||
Net Profit Margin, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
1 2022 Calculation
Net profit margin = 100 × Net income ÷ Revenue
= 100 × ÷ =
2 Click competitor name to see calculations.
- Revenue
- The revenue shows a consistent upward trend over the analyzed periods. Beginning at $445,304 thousand in 2017, it increases each year, reaching $1,031,753 thousand by 2022. This demonstrates steady growth in the company's top-line performance across the six-year span.
- Net Income
- Net income exhibits notable fluctuations. It rises significantly from $52,116 thousand in 2017 to a peak of $259,016 thousand in 2019, followed by a decline in 2020 to $203,009 thousand. Subsequently, it experiences a moderate recovery in 2021, reaching $225,525 thousand, but then declines again to $136,505 thousand in 2022. Despite overall growth relative to 2017, the fluctuations suggest variability in profitability.
- Net Profit Margin
- The net profit margin mirrors the pattern seen in net income, with sharp growth from 11.7% in 2017 to 33.66% in 2019, indicating improved operational efficiency or favorable cost management during this period. However, the margin declines noticeably after 2019, dropping to 24.14% in 2020 and then slightly increasing in 2021 to 26.61%, before falling further to 13.23% in 2022. This trend may reflect rising costs, pricing pressures, or other factors affecting profitability despite increased revenue.
- Overall Insights
- The company demonstrates strong revenue growth consistently over the years, suggesting expanding business operations or market demand. However, the net income and profit margin fluctuations indicate periods of varying profitability, with a peak around 2019 followed by a downturn. The decline in profitability ratios in the most recent year suggests emerging challenges that may require management attention to sustain earnings growth and margin stability.
Return on Equity (ROE)
Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||
Net income | |||||||
Stockholders’ equity | |||||||
Profitability Ratio | |||||||
ROE1 | |||||||
Benchmarks | |||||||
ROE, Competitors2 | |||||||
Abbott Laboratories | |||||||
Elevance Health Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
ROE, Sector | |||||||
Health Care Equipment & Services | |||||||
ROE, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
1 2022 Calculation
ROE = 100 × Net income ÷ Stockholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Income
- The net income exhibited considerable growth between March 2017 and March 2019, increasing from $52,116 thousand to $259,016 thousand. However, after peaking in 2019, net income declined in 2020 to $203,009 thousand, showed a small recovery in 2021 to $225,525 thousand, and decreased significantly again in 2022 to $136,505 thousand. This pattern suggests volatility in profitability during the later years despite earlier strong growth.
- Stockholders’ Equity
- Stockholders’ equity demonstrated a consistent upward trend over the entire period. Starting at $452,071 thousand in 2017, it steadily increased to $1,503,326 thousand by 2022. This continuous growth indicates increasing net assets attributed to shareholders, reflecting overall capital strengthening, possibly due to retained earnings and additional equity financing.
- Return on Equity (ROE)
- ROE rose from 11.53% in 2017 to a peak of 27.65% in 2019, paralleling the surge in net income during the same time frame. After 2019, ROE declined notably to 19.05% in 2020 and further to 16.96% in 2021, reaching the lowest point of 9.08% in 2022. The decline in ROE despite increasing stockholders’ equity indicates reduced profitability relative to shareholders’ equity in recent years.
- Overall Analysis
- The data indicates a period of strong financial performance from 2017 to 2019, characterized by rapid growth in net income and improving ROE. Post-2019, the company experienced decreased profitability while continuing to build equity. The decline in ROE alongside rising equity and fluctuating net income suggests challenges in generating returns from shareholder capital during the latest years.
Return on Assets (ROA)
Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||
Net income | |||||||
Total assets | |||||||
Profitability Ratio | |||||||
ROA1 | |||||||
Benchmarks | |||||||
ROA, Competitors2 | |||||||
Abbott Laboratories | |||||||
Elevance Health Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
ROA, Sector | |||||||
Health Care Equipment & Services | |||||||
ROA, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
1 2022 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Income
- The net income showed a strong upward trend from 2017 to 2019, increasing from 52,116 thousand USD to a peak of 259,016 thousand USD in 2019. This was followed by a decline in 2020 to 203,009 thousand USD. There was a slight recovery in 2021 to 225,525 thousand USD, but net income decreased significantly again in 2022, falling to 136,505 thousand USD.
- Total Assets
- Total assets consistently increased throughout the entire period, rising steadily from 550,414 thousand USD in 2017 to 1,673,393 thousand USD in 2022. This indicates continuous asset growth each year without any decline.
- Return on Assets (ROA)
- Return on assets experienced considerable fluctuations over the years. It improved substantially from 9.47% in 2017 to a high of 24.57% in 2019. Following this peak, ROA declined sharply to 16.69% in 2020 and continued to decrease to 15.09% in 2021. The most noticeable drop occurred in 2022, with ROA falling to 8.16%, the lowest level in the observed period.
- Overall Analysis
- The data indicates robust growth in net income and asset base from 2017 through 2019, with a particularly strong performance in 2019. However, starting in 2020, net income and ROA showed signs of weakening despite continued asset growth, suggesting challenges in asset efficiency or profitability. The consistent increase in total assets implies ongoing investment or expansion, but the declining ROA and net income in the later years highlight potential issues with generating commensurate returns from these assets. The significant decline in 2022 net income and ROA raises concerns regarding recent operational performance or market conditions.